US Pharma MarketingBristol Myers claims Phase 2 success for GPRC5D-directed CAR-T
An experimental CAR-T called arlo-cel improved response rates in patients with relapsed and refractory multiple myeloma who had received at least four previous therapies. Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR and gene editing:…
CAR-T therapy has revolutionized blood cancer treatment, particularly in multiple myeloma. But an ongoing concern remains: If patients’ cancers progress after receiving CAR-T, what other options do they have?
A Phase 2 study at Bristol ...
Source: Endpoints News